| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/27/2006 | US20060165757 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/27/2006 | US20060165755 Method for treating otitis externa |
| 07/27/2006 | US20060165747 Antifungal composition, method and kit for topically treating onychomycosis |
| 07/27/2006 | US20060165734 Novel method of deodorization for fat odor and composition obtained by the same |
| 07/27/2006 | US20060165733 Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol |
| 07/27/2006 | US20060165720 Drug product for diabetes |
| 07/27/2006 | US20060165718 Immunizing compositions and methods of use |
| 07/27/2006 | US20060165704 Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody |
| 07/27/2006 | US20060165701 Agents for the diagnosis and treatment of tumors that expose alerted proteins on the cell surface |
| 07/27/2006 | US20060165700 Cancer therapy using whole glucan particles and antibodies |
| 07/27/2006 | US20060165699 Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165684 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions; inhibiting proliferation of peripheral blood mononuclear cells |
| 07/27/2006 | US20060165683 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 07/27/2006 | US20060165672 Fatigue reducing agent |
| 07/27/2006 | US20060165671 Novel nutraceutical compositions comprising epigallocatechin gallate |
| 07/27/2006 | US20060165670 Synbiotic combination |
| 07/27/2006 | US20060165659 detecting a reduction in gene copy number, by determining gene mutational status, or by detecting a reduction in the RNA transcribed from these genes; inhibition of neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells |
| 07/27/2006 | US20060165657 Method for delivery of cosmetic by topical application |
| 07/27/2006 | US20060165656 Medicinal preparation having chemotherapeutic encapsulated therein |
| 07/27/2006 | US20060165655 4-Amino-7- beta -(2'-C-methyl-D-ribofuranosyl)-furo[3,2-d]pyrimidine; anticancer agents |
| 07/27/2006 | US20060165652 Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| 07/27/2006 | US20060165649 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 07/27/2006 | US20060165647 Immunosuppressive substance adsorbent, extracorporeal cicrulation column and method of treating cancer |
| 07/27/2006 | US20060165619 Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient |
| 07/27/2006 | US20060165617 Cosmetic Composition and Method |
| 07/27/2006 | US20060165612 Compositions for hygienic hand disinfection and disinfectant handwashing |
| 07/27/2006 | US20060165610 Composition for Treating and Preventing Periodontal Disease and Method of Use |
| 07/27/2006 | US20060165609 Periodontal ligament-protecting agent |
| 07/27/2006 | US20060165604 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant; migraines |
| 07/27/2006 | US20060165602 Method for deterring abuse of opioids by combination with non-release formulation of emetic |
| 07/27/2006 | US20060165600 Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
| 07/27/2006 | US20060165591 Metal complex-containing pharmaceutical agents |
| 07/27/2006 | US20060163159 Chlorinating o-tolylacetic acid with sulfuryl chloride or chlorine gas, hydroxylation to 2-hydroxymethyl phenylacetic acid, salt formation, acidification, solvent extraction, phase separation of 3-isochromanone; by-product inhibition |
| 07/27/2006 | DE112004001860T5 Disulfid-,Sulfid-,Sulfoxid- und Sulfonderivate von cyclischen Zuckern und Verwendungen davon Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof |
| 07/27/2006 | DE112004001563T5 Säure-haltige Oxaliplatin-Formulierungen Acid-containing oxaliplatin formulations |
| 07/27/2006 | DE102005002662A1 Use of ascorbigen as an agent for the reduction of aging processes and for the treatment of e.g. prostate cancer and osteoporosis |
| 07/27/2006 | DE102005002500A1 Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen Tetrahydrofuran derivatives as inhibitors of matrix metalloproteinases |
| 07/27/2006 | DE102005001411A1 Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament Substituted 4-Phenyltetrahydroisochinoline, processes for their preparation, their use as a medicament, and medicament containing them |
| 07/27/2006 | CA2619153A1 Regulation of protein synthesis by inhibition of eif4e-eif4g interaction |
| 07/27/2006 | CA2604394A1 Hyaluronic acid derivative and neural stem cells for sci and pnt regeneration |
| 07/27/2006 | CA2601380A1 Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| 07/27/2006 | CA2601357A1 Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases |
| 07/27/2006 | CA2601326A1 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1(glyt-i) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 07/27/2006 | CA2595599A1 Methods for qt interval control |
| 07/27/2006 | CA2595574A1 Chemical compounds |
| 07/27/2006 | CA2595528A1 Method of treatment by administration of rna |
| 07/27/2006 | CA2595523A1 Method of genotypically modifying cells by administration of rna |
| 07/27/2006 | CA2595486A1 Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| 07/27/2006 | CA2595483A1 Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
| 07/27/2006 | CA2595481A1 A tetracycline metal complex in a solid dosage form |
| 07/27/2006 | CA2595477A1 Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| 07/27/2006 | CA2595472A1 Novel coumarin derivatives as ion channel openers |
| 07/27/2006 | CA2595470A1 Pharmaceutical formulations and methods of use |
| 07/27/2006 | CA2595469A1 A method of treating cellular damage |
| 07/27/2006 | CA2595461A1 Method for producing albumin conjugates containing gyrase inhibitors |
| 07/27/2006 | CA2595458A1 Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same |
| 07/27/2006 | CA2595403A1 Modulation of th2 lineage commitment by t-bet |
| 07/27/2006 | CA2595400A1 Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions |
| 07/27/2006 | CA2595329A1 Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
| 07/27/2006 | CA2595237A1 Stable prostaglandin-containing compositions |
| 07/27/2006 | CA2595236A1 A method for treating neurologic diseases |
| 07/27/2006 | CA2595224A1 Novel quinolinium salts and derivatives |
| 07/27/2006 | CA2595208A1 Therapeutic agents for sensory disorders |
| 07/27/2006 | CA2595173A1 N-substituted heterocyclic sulfonamides |
| 07/27/2006 | CA2595157A1 Imidazole and benzimidazole derivatives useful as histamine h3 antagonists |
| 07/27/2006 | CA2595130A1 Mitotic kinesin inhibitors |
| 07/27/2006 | CA2595127A1 Mitotic kinesin inhibitors |
| 07/27/2006 | CA2595045A1 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application |
| 07/27/2006 | CA2595043A1 Use of oxycodone for treating visceral pain |
| 07/27/2006 | CA2595041A1 Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use |
| 07/27/2006 | CA2594981A1 Anthelmintic composition |
| 07/27/2006 | CA2594946A1 Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease |
| 07/27/2006 | CA2594943A1 Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/27/2006 | CA2594940A1 Cgrp receptor antagonists |
| 07/27/2006 | CA2594910A1 Compositions and methods relating to mitochondrial hyperpolarization in neurological disease |
| 07/27/2006 | CA2594878A1 Indoles useful in the treatment of inflammation |
| 07/27/2006 | CA2594785A1 Crystalline forms cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-a-yloxy) nicotinamide |
| 07/27/2006 | CA2594781A1 Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases |
| 07/27/2006 | CA2594777A1 Indoles useful in the treatment of inflamation |
| 07/27/2006 | CA2594773A1 Indoles useful in the treatment of inflammation |
| 07/27/2006 | CA2594665A1 Thienopyrroles useful in the treatment of inflammation |
| 07/27/2006 | CA2594621A1 Pyrrolopyridines useful in the treatment of inflammation |
| 07/27/2006 | CA2594567A1 Fluoroalkylpyrrolidine derivative |
| 07/27/2006 | CA2594563A1 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| 07/27/2006 | CA2594487A1 5-aminoindole derivatives |
| 07/27/2006 | CA2594482A1 Antitumor agent |
| 07/27/2006 | CA2594477A1 Pharmaceutical compounds |
| 07/27/2006 | CA2594474A1 Pharmaceutical compounds |
| 07/27/2006 | CA2594310A1 Use of resolvins to treat gastrointestinal diseases |
| 07/27/2006 | CA2594297A1 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 07/27/2006 | CA2593656A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | CA2593560A1 4- (2, 6-dichlorobenzoylamino) -lh-pyrazole-3 -carboxylic acid piperidin- 4 -ylamid acid addition salts as kinase inhibitors |
| 07/27/2006 | CA2593483A1 Methods of use of dual ppar agonist compounds and drug delivery devices containing such compounds |
| 07/27/2006 | CA2593475A1 Combinations of pyrazole kinase inhibitors and further antitumor agents |
| 07/27/2006 | CA2593468A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | CA2593465A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | CA2593359A1 Direct compression formulation and process |
| 07/27/2006 | CA2593166A1 Mitotic kinesin inhibitors |
| 07/27/2006 | CA2593155A1 Indoles useful in the treatment of inflammation |